Is Dyne Therapeutics, Inc. (DYN) a Buy, Sell, or Hold?
NASDAQ : DYN
Dyne Therapeutics, Inc.
$25.9232 USD
$0.68 (2.71%)
- Volume
- 1.36M
- Average Volume
- 2.05M
- Market Capitalization
- $4.84B
- P/E Ratio
- -7.78
- Dividend Yield
- 0.00%
- Price Target
- $35.50
- Year High
- $26.26
- Year Low
- $9.89
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $12.02
Company Overview
NASDAQ
John G. Cox
Biotechnology
Healthcare
DYN
258
US
USD
Liquidity Metrics
0.03
12.02
12.02
8.66
0.00
Sales & Valuation
-$
0.00
6.11
-9.70
-3.02
Profitability
-$3.47
-$446.21M
0.00%
0.00%
-64.30%
-52.25%
P/E Metrics
-7.78
-0.54
-0.54
Analyst Price Target & Rating
$35.50
$45.00
$24.00
2/5
14 Analysts
-26.98%
Financial Health Scores
6.69
2/9
$859.86M
$994.01M
$291.86M
-$497.5M
Key Metrics (TTM)
$4.06B
0.00
-8.19
12.02
-64.30%
-58.28%
-12.44%
-10.59%
-8514 days
Company Executives
| Name | Title |
|---|---|
| Oxana Beskrovnaya | Chief Innovation Officer |
| Rajesh Manchanda | Chief Technical Officer |
| James Bilotta | Chief Digital & Information Officer |
| Debra Feldman | Chief Regulatory Affairs Officer |
| Lucia Celona | Chief Human Resource Officer |
| Douglas Kerr | Chief Medical Officer |
| John G. Cox | Chief Executive Officer, President & Director |
| Erick J. Lucera | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer |
| Johanna Friedl-Naderer | Chief Commercial Officer |
| Daniel Wilson | Senior Vice President & Head of Legal |
| Axel Wiest | Senior VP and Head of Portfolio Strategy & Operations |
Poll Results
No votes yet today — be the first to share your view!
About Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts. ...
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-07-29 16:30:00
- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 -
2026-07-28 07:30:00
- Company's third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease -
Fifth Third Bancorp Buys New Shares in Dyne Therapeutics, Inc. $DYN
2026-07-27 04:03:46
Fifth Third Bancorp purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ: DYN) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 54,229 shares of the company's stock, valued at approximately $983,000. Several other institutional investors and hedge funds have also recently added
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-24 16:05:00
WALTHAM, Mass., July 24, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 12 newly hired employees. The awards were made as an inducement material to the newly hired employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).
2026-07-23 16:05:00
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,045,000 shares of its common stock at a public offering price of $20.50 per share, which includes 2,745,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering.
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
2026-07-21 22:46:14
WALTHAM, Mass. , July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,300,000 shares of its common stock at a public offering price of $20.
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
2026-07-21 22:46:00
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,300,000 shares of its common stock at a public offering price of $20.50 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $375,150,000. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 23, 2026, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 2,745,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
2026-07-21 16:46:00
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne.
Frequently Asked Questions
-
What is the current Dyne Therapeutics, Inc. (DYN) stock price?
-
Dyne Therapeutics, Inc.(NASDAQ:DYN) stock price is $25.9232 in the last trading session. During the trading session, DYN stock reached the peak price of $26.26 while $9.89 was the lowest point it dropped to. The percentage change in DYN stock occurred in the recent session was 2.71% while the dollar amount for the price change in DYN stock was $0.68.
-
DYN's industry and sector of operation?
-
The NASDAQ listed DYN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DYN?
-
Oxana Beskrovnaya | Chief Innovation Officer
Rajesh Manchanda | Chief Technical Officer
James Bilotta | Chief Digital & Information Officer
Debra Feldman | Chief Regulatory Affairs Officer
Lucia Celona | Chief Human Resource Officer -
How many employees does DYN have?
-
Number of DYN employees currently stands at 258. DYN operates from 1560 Trapelo Road, Waltham, MA 02451, US.
-
Link for DYN official website?
-
Official Website of DYN is: https://www.dyne-tx.com
-
How do I contact DYN?
-
DYN could be contacted at phone #781 786 8230 and can also be accessed through its website. DYN operates from 1560 Trapelo Road, Waltham, MA 02451, US.
-
How many shares of DYN are traded daily?
-
The average number of DYN shares traded daily for last 3 months was 2.05M.
-
What is the market cap of DYN currently?
-
The market value of DYN currently stands at $4.84B with its latest stock price at $25.9232